Angel Biotech signs new contract with ReNeuron

Angel Biotechnology, a manufacturer of stem cells for medical research, has announced a new contract with ReNeuron for completion in the current financial year.

The contract is to supply clinical material for ReNeuron's research trials using stem cells to treat stroke patients.

ReNeuron's ReN001 stem cell therapy is being administered in ascending doses to a total of 12 stroke patients who have been left disabled by an ischaemic stroke, the most common form of the condition.

Try 6 free issues of MoneyWeek today

Get unparalleled financial insight, analysis and expert opinion you can profit from.

Start your trial

Sign up for MoneyWeek’s free twice-daily newsletter.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Join more than 165,000 subscribers and keep yourself informed with latest financial news, insights and expert analysis to help you understand what really matters when it comes to your finances.

Sign up

On October 17th, Sharecast reported that news of progress in these trials would have a positive read-across for Angel, which has been supplying stem cells used in these trials.

CM